-
公开(公告)号：WO2023086438A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/049489
申请日：2022-11-10
Applicant: EMORY UNIVERSITY
Inventor： LIOTTA, Dennis , FRITZEMEIER, Russell , VAN DER WESTHUYZEN, Alet , HODSON, Luke E.
Abstract: Prodrugs of neurosteroid analogs are disclosed. Pharmaceutical formulations containing the prodrugs are also disclosed. Additionally, methods of treating a condition, disorder, or disease using the prodrugs or their pharmaceutical formulations are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, CNS injury, concussion, traumatic brain injury, depression, postpartum depression, epilepsy, seizure disorder, and neurodegenerative disease.
-
公开(公告)号：WO2023086431A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/049478
申请日：2022-11-10
Applicant: APNIMED, INC. (DELAWARE)
Inventor： MILLER, Lawrence, G. , FARKAS, Ronald , TARANTO-MONTEMURRO, Luigi , WHITE, David, P.
IPC: A61K31/138 , A61K31/433 , A61K31/496 , A61K31/5375 , A61P11/00 , A61P25/00
Abstract: Pharmaceutical compositions comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a carbonic anhydrase inhibitor (CAI), in the absence of an antimuscarinic agent, and methods of treating conditions associated with pharyngeal airway collapse are described herein.
-
公开(公告)号：WO2023085420A1
公开(公告)日：2023-05-19
申请号：PCT/JP2022/042198
申请日：2022-11-14
Applicant: 学校法人自治医科大学
IPC: C07D221/18 , A61K31/473 , A61K31/4741 , A61P1/16 , A61P3/00 , A61P3/10 , A61P5/00 , A61P9/10 , A61P11/00 , A61P13/02 , A61P13/12 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P27/02 , A61P31/04 , A61P43/00 , C07D491/06
Abstract: 本発明は、ミトコンドリアの機能障害に起因する症状、疾患若しくは障害の発現機序を明らかにし、同様の発現機序に関連する症状、疾患若しくは障害を予防又は治療し得る手段を提供する。本発明の一態様は、式（I）で表される化合物若しくはその製薬上許容される塩、又はそれらの製薬上許容される溶媒和物を有効成分として含有する、フェロトーシス阻害剤に関する。本発明の別の一態様は、フェロトーシス阻害剤を有効成分として含有する、フェロトーシスに関連する症状、疾患若しくは障害の予防又は治療に使用するための医薬に関する。本発明のさらに別の一態様は、式（I-1）で表される化合物若しくはその塩、又はそれらの溶媒和物に関する。
-
公开(公告)号：WO2023082003A1
公开(公告)日：2023-05-19
申请号：PCT/CA2022/051659
申请日：2022-11-10
Inventor： MOUSTAFA, Mahmoud Mohamed Abdrabo
IPC: C07C229/08 , A61K47/55 , A61P25/00 , C07C229/28 , C07C271/48 , C07C271/54
Abstract: Cannabinoid-gabapentinoid conjugates and their formulations possessing dual synergistic pharmacological effects to control neuropathic pain, multiple sclerosis, seizures and postherpetic neuralgia, restless leg syndrome, trigeminal neuralgia, fibromyalgia, diabetic neuropathy, anxiety and bipolar disorders, schizophrenia, sleep disorders, and other related pathological conditions. The conjugates improve the therapeutic potential for both component compounds, while reducing the addiction and substance abuse problems commonly observed with each component, when prescribed independently, thereby providing a solution for cannabinoid and gabapentinoid substance abuse disorders.
-
公开(公告)号：WO2023081633A1
公开(公告)日：2023-05-11
申请号：PCT/US2022/079028
申请日：2022-11-01
Applicant: UNIVERSITY OF ROCHESTER
Inventor： GOLDMAN, Steven , BENRAISS, Abdellatif , MARIANI, John
Abstract: The present application relates to a method of treating a subject having a condition mediated by a deficiency in myelin. This method involves selecting a subject having a condition mediated by a deficiency in myelin and expressing a transcription factor 7-like 2 (TCF7L2) protein in the selected subject under conditions effective to treat the condition. Also disclosed is a method of increasing oligodendrocyte production from glial progenitor cells. This method involves providing a population of glial progenitor cells and expressing a TCF7L2 protein in the provided population of glial progenitor cells under conditions effective to increase oligodendrocyte production compared to oligodendrocyte production absent said administering. Also disclosed is a genetic construct suitable, inter alia, for carrying out these methods.
-
Patent Agency Ranking
公开(公告)号：WO2023078392A1
公开(公告)日：2023-05-11
申请号：PCT/CN2022/129881
申请日：2022-11-04
Applicant: 上海翰森生物医药科技有限公司 , 江苏豪森药业集团有限公司
IPC: C07D265/30 , A61K31/5377 , A61P25/00
Abstract: 涉及2-(芳基-2-基)吗啉及其氘代衍生物、制备方法和应用。特别地，涉及式(V)化合物在治疗中枢神经系统疾病中的用途、及其氘代化合物、氘代化合物的制备方法及含有氘代化合物的药物组合物，及其作为TAAR1激动剂在治疗中枢神经系统疾病中的用途。
-
公开(公告)号：WO2023076812A1
公开(公告)日：2023-05-04
申请号：PCT/US2022/078245
申请日：2022-10-18
Applicant: ANEURYST, INC.
Inventor： MOSES, Ziev, B.
IPC: A61K31/47 , A61K31/551 , A61P25/00
Abstract: Disclosed herein are compounds and methods for the treatment of disturbances to cerebral homeostasis using isoquinoline derivatives and pharmaceutical compositions thereof.
-
-
9.发明申请
公开(公告)号：WO2023069790A1
公开(公告)日：2023-04-27
申请号：PCT/US2022/047624
申请日：2022-10-24
Applicant: SANA BIOTECHNOLOGY, INC.
Inventor： FRY, Terry J. , JOHNSON, Adam James , DOWDLE, William
IPC: A61K35/17 , C12N5/0783 , C12N15/90 , A61P3/10 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/28 , A61P35/00 , A61P37/06
Abstract: Provided herein are methods of producing a composition comprising genetically engineered cells for cell therapy, the method comprising: selecting one or more genetically engineered cells from a population of cells, and formulating the composition comprising the selected one or more genetically engineered cells for use, wherein the one or more genetically engineered cells comprise one or more genetic modifications, and wherein the one or more genetically engineered cells are selected based on a level of one or more markers on the cell surface of the one or more genetically engineered cells, as well as compositions derived therefrom.
-
公开(公告)号：WO2023068363A1
公开(公告)日：2023-04-27
申请号：PCT/JP2022/039307
申请日：2022-10-21
Applicant: 森永乳業株式会社
IPC: A61K35/745 , A23L33/135 , A61P25/00 , A61P25/28 , C12N1/20
Abstract: この脳萎縮抑制剤は、健常者、軽度認知障害と診断された者、認知機能低下と評価された者及び神経変性疾患に罹患する恐れがある対象から選択されるいずれかの対象に投与するための、Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ｂｒｅｖｅ ＭＣＣ１２７４（ＦＥＲＭ ＢＰ－１１１７５）を含む培養物を有効成分とする。
-
-
-
-
-
-
-
-
-
Search Results
17656
records
(took 0.054 seconds)
